- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03784456
Impact of Increased Protein Density Diet to Muscle Mass and Strength Among Mid-aged and Older Adults
The subjects of this intervention program are mainly based on community-dwelling mid-aged and older adults. The investigator's program will provide meals containing different proportionated protein.As this project is a double blind test, only the investigators will know which subject corresponding to specific group of diets.
Besides, the investigators use the valued-based healthcare standard set as well as the Center for Epidemiological Studies-Depression, Charlson's comorbidity index Montreal Cognitive Assesment ,and Mini Nutritional Assessment as outcome measures and to use the randomized controlled trial design to validate if increased protein density diet could improve the vitality and health of mid-aged and old adults .
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Taipei, Taiwan, 112
- National Yang Ming University
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- People who aged 40-75 years
- Patients with following characteristics:
- feeling loss in activity
- detecting decline in self's walking speed.
- feeling tired of doing everything.
- having fell in last year.
- People can accept undergoing MRI
- People willing to follow the program and cooperate with us for following tracking.
- People who are neither vegan nor vegetarian
- People agree and be able to sign the informed consent.
Exclusion Criteria:
- People cannot intake provided meals (e.g.: vegans or vegetarians) or any other who is allergic to our diets.
- People with any disease affecting their limbs, including:
- having fracture on limbs in the past 6 months
- having severe arthritis in the past 6 months
- any other whom PI recognized as weak control of their nervous system( e.g.: Parkinson's disease and stroke).
- People with intermittent limp caused by peripheral artery diseases
- People with weak control of mental disorder
- People with weak control of Cardiopulmonary disease
- People with weak control of Malignant tumor
- People with weak control of kidney diseases (eGFR <60ml/min/1.73)
- People with Visual impairment and Hearing disorder which cannot help to complete the program.
- People who are unable to undertake MRI
- People who have underwent hormone treatment and planned to undergo hormone treatment during program session.
- Any other condition that PI recognized as not suitable
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: 25% protein group
This experimental arm will be given meals containing 25% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product.
The meals would be provided 2 times per day, 5 days per week.
The program will last for 12 weeks.
|
Compared to usual group of 15% protein in meals, intervention group will receive 25% protein contents under same estimated calorie menus.
Protein may come from either egg, meat, fish, soy, or milk product.
|
Aktiv komparator: 15% protein group
This control arm will be given meals containing 15% protein under same estimated calorie menus and protein may come from either egg, meat, fish, soy, or milk product.
The meals would be provided 2 times per day, 5 days per week.
The program will last for 12 weeks.
|
Designed as comparator , compared to empirical arm of 25% protein in meals, intervention group will receive 15% protein contents under same estimated calorie menus.
Protein may come from either egg, meat, fish, soy, or milk product.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Ændring fra baseline udholdenhed efter 12 uger
Tidsramme: baseline, 12 uger
|
målt på 6 minutters gåafstand
|
baseline, 12 uger
|
Ændring fra baseline ganghastighed efter 12 uger
Tidsramme: baseline, 12 uger
|
målt ved seks meters ganghastighed
|
baseline, 12 uger
|
Changes from baseline muscle strength after 12 weeks
Tidsramme: baseline,12 weeks
|
measured by hand grip
|
baseline,12 weeks
|
Changes form baseline QUALITY OF LIFE after 12 weeks
Tidsramme: baseline, 12 weeks
|
measured by the 36-Item Short Form Health Survey (SF-36), ranged 0-100, higher values represent a better condition
|
baseline, 12 weeks
|
Change from baseline Nutrition intake after 12 weeks
Tidsramme: baseline, 12 weeks.
|
measured by Mini-nutritional assessment questionnaire.
ranged 0-30, higher values represent a better condition
|
baseline, 12 weeks.
|
Change from baseline depression after 12 weeks
Tidsramme: baseline,12 weeks
|
measured by the Center for Epidemiological Studies-Depression (CES-D) ranged 0-60, higher values represent a worse condition
|
baseline,12 weeks
|
Change from baseline cognitive ability after 12 weeks
Tidsramme: baseline, 12 weeks
|
measured by Montreal Cognitive Assessment (MoCA) , ranged 0-30, higher values represent a better condition
|
baseline, 12 weeks
|
Change from baseline timed up and go test after 12 weeks
Tidsramme: baseline, 12 weeks
|
measured by timed up and go test (TUG) and six-meter walking speed
|
baseline, 12 weeks
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Ændring fra baseline-tal for fuldstændig blodtælling efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline-tal for fuldstændig blodtælling efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline-koncentrationen af Albumin efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline-koncentrationen af Albumin efter 12 uger
|
baseline, 12 uger
|
Ændring fra baselinekoncentrationen af urinstofnitrogen i blodet efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baselinekoncentrationen af urinstofnitrogen i blodet efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline-koncentrationen af kreatinin efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline-koncentrationen af kreatinin efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline-koncentrationen af fastende glukose efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline-koncentrationen af fastende glukose efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline koncentration af total kolesterol efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline koncentration af total kolesterol efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline-koncentrationen af triglycerid efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline-koncentrationen af triglycerid efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline koncentration af high-density lipoprotein kolesterol efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline koncentration af high-density lipoprotein kolesterol efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline-koncentrationen af lavdensitetslipoproteinkolesterol efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline-koncentrationen af lavdensitetslipoproteinkolesterol efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline koncentration af højfølsomt C-reaktivt protein efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline koncentration af højfølsomt C-reaktivt protein efter 12 uger
|
baseline, 12 uger
|
Ændring fra baseline koncentration af dehydroepiandrosteron efter 12 uger
Tidsramme: baseline, 12 uger
|
Ændring fra baseline koncentration af dehydroepiandrosteron efter 12 uger
|
baseline, 12 uger
|
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
Tidsramme: baseline,12 weeks
|
Change from baseline concentration of Alanine Aminotransferase (ALT) after 12 weeks
|
baseline,12 weeks
|
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
Tidsramme: baseline,12 weeks
|
Change from baseline concentration of Aspartate Aminotransferase (AST) after 12 weeks
|
baseline,12 weeks
|
Change from baseline concentration of Fasting insulin after 12 weeks
Tidsramme: baseline,12 weeks
|
Change from baseline concentration of Fasting insulin after 12 weeks
|
baseline,12 weeks
|
Change from baseline concentration of 25-(OH)-Vit. D after 12 weeks
Tidsramme: baseline, 12 weeks
|
Change from baseline concentration of 25-(OH)-Vit.
D after 12 weeks
|
baseline, 12 weeks
|
Change from baseline concentration of Leptin after 12 weeks
Tidsramme: baseline, 12 weeks
|
Change from baseline concentration of Leptin after 12 weeks
|
baseline, 12 weeks
|
Change from baseline concentration of urine protein after 12 weeks
Tidsramme: baseline, 12 weeks
|
Change from baseline concentration of urine routine after 12 weeks
|
baseline, 12 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 19-001-A-2
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med 25% protein
-
VA Office of Research and DevelopmentAfsluttet
-
VA Office of Research and DevelopmentAfsluttet
-
Solae, LLCAfsluttetHyperkolesterolæmiForenede Stater
-
Cartesian TherapeuticsRekrutteringMyelomatose | Tilbagefaldende myelomatoseForenede Stater, Kalkun
-
Anglia Ruskin UniversityDanone Nutricia ResearchRekrutteringGastrointestinal dysfunktion | AminosyreændringDet Forenede Kongerige
-
USDA Grand Forks Human Nutrition Research CenterAktiv, ikke rekrutterendeFedmeForenede Stater
-
Korea University Guro HospitalKorean Center for Disease Control and PreventionAktiv, ikke rekrutterendeCOVID-19 (sunde frivillige)Korea, Republikken
-
EMSRekrutteringAftøs StomatitisBrasilien
-
University of AarhusArla Foods; Mejeribrugets ForskningsFond; Innovation foundationAfsluttetProteinmetabolismeDanmark
-
Pennington Biomedical Research CenterAfsluttet